The specter of generic challenges has repeatedly loomed over copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of connected drug ventures. While first years saw impressive gains, the intellectual property expiration has opened the way for discounted alternatives, likely lowering revenue and creating a real risk f